Search

Your search keyword '"De Hingh, Ignace"' showing total 1,563 results
Start Over Author "De Hingh, Ignace"
1,563 results on '"De Hingh, Ignace"'

101. Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer

Author

Latenstein, Anouk E.J., Mackay, Tara M., van Huijgevoort, Nadine C.M., Bonsing, Bert A., Bosscha, Koop, Hol, Lieke, Bruno, Marco J., van Coolsen, Marielle M.E., Festen, Sebastiaan, van Geenen, Erwin, Groot Koerkamp, Bas, Hemmink, Gerrit J.M., de Hingh, Ignace H.J.T., Kazemier, Geert, Lubbinge, Hans, de Meijer, Vincent E., Molenaar, I. Quintus, Quispel, Rutger, van Santvoort, Hjalmar C., Seerden, Tom C.J., Stommel, Martijn W.J., Venneman, Niels G., Verdonk, Robert C., Besselink, Marc G., and van Hooft, Jeanin E.

Published
2021
Full Text
View/download PDF

102. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?

Author

Abba, Julio, Afifi, Adnane, Mortensen, Michael Bau, Bharath, G., Bhatt, Aditi, Yan So, Jimmy Bok, Brandl, Andreas, Ceelen, Wim, Cortes-Guiral, Delia, Courvoiser, Thomas, Coget, Julien, de Hingh, Ignace H., Delhorme, Jean-Baptiste, Deo, Suryanarayana S.V., di Giorgio, Andrea, Dumont, Frederic, Escayola, Cecilia, Ezanno, Anne-Cécile, Gagnière, Johan, Galindo, Julio, Glatz, Torben, Jäger, Tarkan, Jarra, Maximilian, Katdare, Ninad, Kepenekian, Vahan, Khomyakov, Vladimir M., Kothonidis, Konstantinos, Laplace, Nathalie, Lavoue, Vincent, Lehmann, Kuno, Lynch, Craig, Mehta, Sanket, Moldovan, Bogdan, Nissan, Aviram, Nowacki, Maciej, Orry, David, Pérez, Gloria Ortega, Pabst, Urs G., Paquette, Brice, Paskonis, Marius, Piso, Pompiliu, Pocard, Marc, Rau, Beate, Reymond, Marc, Ris, Frederic, Robella, Manuela, Silvestre-Rodriguez, José, Singh, Shivendra, Somashekhar, S.P., Soravia, Claudio, Sourrouille, Isabelle, Taibi, Abelkader, Tempfer, Clemens, Torkington, Jared, Vizzielli, Giuseppe, Willaert, Wouter, Sgarbura, Olivia, Villeneuve, Laurent, Alyami, Mohammad, Bakrin, Naoual, Torrent, Juan José, Eveno, Clarisse, and Hübner, Martin

Published
2021
Full Text
View/download PDF

103. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: Protocol of the multicentre, open-label, phase II, INTERACT-II trial

Author

Heelkundig Oncologische Disciplines, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., Burger, Jacobus W.A., Heelkundig Oncologische Disciplines, Lab Translational Oncology, Cancer, Regenerative Medicine and Stem Cells, Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., and Burger, Jacobus W.A.

Published
2024

104. ASO Visual Abstract: Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases-A Nationwide Population-Based Study

Author

MS CGO, Cancer, van der Ven, Roos G.F.M., van den Heuvel, Teun B.M., Rovers, Koen P.B., Nienhuijs, Simon W., Boerma, Djamila, van Grevenstein, Wilhelmina M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva V.E., de Reuver, Philip, Tuynman, Jurriaan B., Cancer Organisation, Utrecht, the Netherlands, Netherlands, de Hingh, Ignace H.J.T., MS CGO, Cancer, van der Ven, Roos G.F.M., van den Heuvel, Teun B.M., Rovers, Koen P.B., Nienhuijs, Simon W., Boerma, Djamila, van Grevenstein, Wilhelmina M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva V.E., de Reuver, Philip, Tuynman, Jurriaan B., Cancer Organisation, Utrecht, the Netherlands, Netherlands, and de Hingh, Ignace H.J.T.

Published
2024

105. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

Author

Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Lab Translational Oncology, Heelkunde Opleiding, Regenerative Medicine and Stem Cells, Rauwerdink, Paulien, van de Vlasakker, Vincent C.J., Wassenaar, Emma C.E., Rovers, Koen P., Los, Maartje, Herbschleb, Karin H., Creemers, Geert Jan M., Thijs, Annemarie M.J., Raicu, Mihaela G., Huysentruyt, Clément J.R., van der Hoeven, Erik J.R.J., Nederend, Joost, Peeters, Rifka Y.M., Deenen, Maarten J., Elias, Sjoerd G., Fijneman, Remond J.A., Constantinides, Alexander, Kranenburg, Onno, Burger, Pim W.A., Nienhuijs, Simon W., Wiezer, René J., Lurvink, Robin J., de Hingh, Ignace H.J.T., Boerma, Djamila, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Lab Translational Oncology, Heelkunde Opleiding, Regenerative Medicine and Stem Cells, Rauwerdink, Paulien, van de Vlasakker, Vincent C.J., Wassenaar, Emma C.E., Rovers, Koen P., Los, Maartje, Herbschleb, Karin H., Creemers, Geert Jan M., Thijs, Annemarie M.J., Raicu, Mihaela G., Huysentruyt, Clément J.R., van der Hoeven, Erik J.R.J., Nederend, Joost, Peeters, Rifka Y.M., Deenen, Maarten J., Elias, Sjoerd G., Fijneman, Remond J.A., Constantinides, Alexander, Kranenburg, Onno, Burger, Pim W.A., Nienhuijs, Simon W., Wiezer, René J., Lurvink, Robin J., de Hingh, Ignace H.J.T., and Boerma, Djamila

Published
2024

106. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis

Author

MS CGO, Cancer, Onderzoek Radiotherapie, Pathologie Pathologen staf, MS Medische Oncologie, MS Radiotherapie, Trialbureau Beeld, MS HOD, Schouten, Thijs J, van Goor, Iris W J M, Dorland, Galina A, Besselink, Marc G, Bonsing, Bert A, Bosscha, Koop, Brosens, Lodewijk A A, Busch, Olivier R, Cirkel, Geert A, van Dam, Ronald M, Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H J T, Intven, Martijn P W, Kazemier, Geert, Liem, Mike S L, van Lienden, Krijn P, Los, Maartje, de Meijer, Vincent E, Patijn, Gijs A, Schreinemakers, Jennifer M J, Stommel, Martijn W J, van Tienhoven, Geert Jan, Verdonk, Robert C, Verkooijen, Helena M, van Santvoort, Hjalmar C, Molenaar, I Quintus, Daamen, Lois A, Dutch Pancreatic Cancer Group, MS CGO, Cancer, Onderzoek Radiotherapie, Pathologie Pathologen staf, MS Medische Oncologie, MS Radiotherapie, Trialbureau Beeld, MS HOD, Schouten, Thijs J, van Goor, Iris W J M, Dorland, Galina A, Besselink, Marc G, Bonsing, Bert A, Bosscha, Koop, Brosens, Lodewijk A A, Busch, Olivier R, Cirkel, Geert A, van Dam, Ronald M, Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H J T, Intven, Martijn P W, Kazemier, Geert, Liem, Mike S L, van Lienden, Krijn P, Los, Maartje, de Meijer, Vincent E, Patijn, Gijs A, Schreinemakers, Jennifer M J, Stommel, Martijn W J, van Tienhoven, Geert Jan, Verdonk, Robert C, Verkooijen, Helena M, van Santvoort, Hjalmar C, Molenaar, I Quintus, Daamen, Lois A, and Dutch Pancreatic Cancer Group

Published
2024

107. Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to 5 Years after Diagnosis

Author

Epi Kanker Team B, Cancer, Biostatistiek Onderwijs, Apotheek Bereidingen, Anatomie, MS CGO, MS Hematologie, MS Medische Oncologie, Epi Kanker, JC onderzoeksprogramma Cancer, Smit, Karel C, Derksen, Jeroen W G, Stellato, Rebecca K, van Lanen, Anne-Sophie, Wesselink, Evertine, Belt, Eric J Th, Cloos-van Balen, Marissa, Coene, Peter Paul L O, Dekker, Jan Willem T, de Groot, Jan Willem, Haringhuizen, Annebeth W, van Halteren, Henk K, van Heek, Tjarda T, Helgason, Helgi H, Hendriks, Mathijs P, de Hingh, Ignace H J T, Hoekstra, Ronald, Houtsma, Danny, Janssen, Johan J B, Kok, Niels, Konsten, Joop L M, Los, Maartje, Meijerink, Martijn R, Mekenkamp, Leonie J M, Peeters, Koen C M J, Polée, Marco B, Rietbroek, Ron C, Schiphorst, Anandi H W, Schrauwen, Ruud W M, Schreinemakers, Jennifer, Sie, Mark P S, Simkens, Lieke, Sonneveld, Eric J A, Terheggen, Frederiek, Valkenburg-van Iersel, Liselot, Vles, Wouter J, Wasowicz-Kemps, Daria K, de Wilt, Johannes H W, Kok, Dieuwertje E, Winkels, Renate M, Kampman, Ellen, van Duijnhoven, Fränzel J B, Koopman, Miriam, May, Anne M, Epi Kanker Team B, Cancer, Biostatistiek Onderwijs, Apotheek Bereidingen, Anatomie, MS CGO, MS Hematologie, MS Medische Oncologie, Epi Kanker, JC onderzoeksprogramma Cancer, Smit, Karel C, Derksen, Jeroen W G, Stellato, Rebecca K, van Lanen, Anne-Sophie, Wesselink, Evertine, Belt, Eric J Th, Cloos-van Balen, Marissa, Coene, Peter Paul L O, Dekker, Jan Willem T, de Groot, Jan Willem, Haringhuizen, Annebeth W, van Halteren, Henk K, van Heek, Tjarda T, Helgason, Helgi H, Hendriks, Mathijs P, de Hingh, Ignace H J T, Hoekstra, Ronald, Houtsma, Danny, Janssen, Johan J B, Kok, Niels, Konsten, Joop L M, Los, Maartje, Meijerink, Martijn R, Mekenkamp, Leonie J M, Peeters, Koen C M J, Polée, Marco B, Rietbroek, Ron C, Schiphorst, Anandi H W, Schrauwen, Ruud W M, Schreinemakers, Jennifer, Sie, Mark P S, Simkens, Lieke, Sonneveld, Eric J A, Terheggen, Frederiek, Valkenburg-van Iersel, Liselot, Vles, Wouter J, Wasowicz-Kemps, Daria K, de Wilt, Johannes H W, Kok, Dieuwertje E, Winkels, Renate M, Kampman, Ellen, van Duijnhoven, Fränzel J B, Koopman, Miriam, and May, Anne M

Published
2024

108. Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases

Author

Lab Translational Oncology, Dienst Geestelijke Verzorging, Heelkunde Opleiding, Genetica, CMM Groep Cuppen, Cancer, Regenerative Medicine and Stem Cells, Bootsma, Sanne, Dings, Mark P.G., Kesselaar, Job, Helderman, Roxan F.C.P.A., van Megesen, Kyah, Constantinides, Alexander, Moreno, Leandro Ferreira, Stelloo, Ellen, Scutigliani, Enzo M., Bokan, Bella, Torang, Arezo, van Hooff, Sander R., Zwijnenburg, Danny A., Wouters, Valérie M., van de Vlasakker, Vincent C.J., Galanos, Laskarina J.K., Nijman, Lisanne E., Logiantara, Adrian, Veenstra, Veronique L., Schlingemann, Sophie, van Piggelen, Sterre, van der Wel, Nicole, Krawczyk, Przemek M., Platteeuw, Johannes J., Tuynman, Jurriaan B., de Hingh, Ignace H., Klomp, Jan P.G., Oubrie, Arthur, Snaebjornsson, Petur, Medema, Jan Paul, Oei, Arlene L., Kranenburg, Onno, Elbers, Clara C., Lenos, Kristiaan J., Vermeulen, Louis, Bijlsma, Maarten F., Lab Translational Oncology, Dienst Geestelijke Verzorging, Heelkunde Opleiding, Genetica, CMM Groep Cuppen, Cancer, Regenerative Medicine and Stem Cells, Bootsma, Sanne, Dings, Mark P.G., Kesselaar, Job, Helderman, Roxan F.C.P.A., van Megesen, Kyah, Constantinides, Alexander, Moreno, Leandro Ferreira, Stelloo, Ellen, Scutigliani, Enzo M., Bokan, Bella, Torang, Arezo, van Hooff, Sander R., Zwijnenburg, Danny A., Wouters, Valérie M., van de Vlasakker, Vincent C.J., Galanos, Laskarina J.K., Nijman, Lisanne E., Logiantara, Adrian, Veenstra, Veronique L., Schlingemann, Sophie, van Piggelen, Sterre, van der Wel, Nicole, Krawczyk, Przemek M., Platteeuw, Johannes J., Tuynman, Jurriaan B., de Hingh, Ignace H., Klomp, Jan P.G., Oubrie, Arthur, Snaebjornsson, Petur, Medema, Jan Paul, Oei, Arlene L., Kranenburg, Onno, Elbers, Clara C., Lenos, Kristiaan J., Vermeulen, Louis, and Bijlsma, Maarten F.

Published
2024

109. Assessing quality of hepato-pancreato-biliary surgery: nationwide benchmarking

Author

de Graaff, Michelle R., Hendriks, Tessa E., Wouters, Michel, Nielen, Mark, de Hingh, Ignace, Koerkamp, Bas Groot, van Santvoort, Hjalmar C., Busch, Olivier R., den Dulk, Marcel, Klaase, Joost M., van Zwet, Erik, Bonsing, Bert A., Grünhagen, Dirk J., Besselink, Marc G., Kok, Niels F.M., de Graaff, Michelle R., Hendriks, Tessa E., Wouters, Michel, Nielen, Mark, de Hingh, Ignace, Koerkamp, Bas Groot, van Santvoort, Hjalmar C., Busch, Olivier R., den Dulk, Marcel, Klaase, Joost M., van Zwet, Erik, Bonsing, Bert A., Grünhagen, Dirk J., Besselink, Marc G., and Kok, Niels F.M.

Abstract

Background: Clinical auditing is a powerful tool to evaluate and improve healthcare. Deviations from the expected quality of care are identified by benchmarking the results of individual hospitals using national averages. This study aimed to evaluate the use of quality indicators for benchmarking hepato-pancreato-biliary (HPB) surgery and when outlier hospitals could be identified. Methods: A population-based study used data from two nationwide Dutch HPB audits (DHBA and DPCA) from 2014 to 2021. Sample size calculations determined the threshold (in percentage points) to identify centres as statistical outliers, based on current volume requirements (annual minimum of 20 resections) on a two-year period (2020–2021), covering mortality rate, failure to rescue (FTR), major morbidity rate and textbook/ideal outcome (TO) for minor liver resection (LR), major LR, pancreaticoduodenectomy (PD) and distal pancreatectomy (DP). Results: In total, 10 963 and 7365 patients who underwent liver and pancreatic resection respectively were included. Benchmark and corresponding range of mortality rates were 0.6% (0 −3.2%) and 3.3% (0–16.7%) for minor and major LR, and 2.7% (0–7.0%) and 0.6% (0–4.2%) for PD and DP respectively. FTR rates were 5.4% (0–33.3%), 14.2% (0–100%), 7.5% (1.6%–28.5%) and 3.1% (0–14.9%). For major morbidity rate, corresponding rates were 9.8% (0–20.5%), 28.1% (0–47.1%), 36% (15.8%–58.3%) and 22.3% (5.2%–46.1%). For TO, corresponding rates were 73.6% (61.3%–94.4%), 54.1% (35.3–100), 46.8% (25.3%–59.4%) and 63.3% (30.7%–84.6%). Mortality rate thresholds indicating a significant outlier were 8.6% and 15.4% for minor and major LR and 14.2% and 8.6% for PD and DP. For FTR, these thresholds were 17.9%, 31.6%, 22.9% and 15.0%. For major morbidity rate, these thresholds were 26.1%, 49.7%, 57.9% and 52.9% respectively. For TO, lower thresholds were 52.5%, 32.5%, 25.8% and 41.4% respectively. Higher hospital volumes decrease thresholds to detect outliers. Conclusion: Curre

Published
2024

110. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases:A Nationwide Population-Based Study

Author

van der Ven, Roos G.F.M., van den Heuvel, Teun B.M., Rovers, Koen P.B., Nienhuijs, Simon W., Boerma, Djamila, van Grevenstein, Wilhelmina M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva V.E., de Reuver, Philip, Tuynman, Jurriaan B., van Erning, Felice N., de Hingh, Ignace H.J.T., van der Ven, Roos G.F.M., van den Heuvel, Teun B.M., Rovers, Koen P.B., Nienhuijs, Simon W., Boerma, Djamila, van Grevenstein, Wilhelmina M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva V.E., de Reuver, Philip, Tuynman, Jurriaan B., van Erning, Felice N., and de Hingh, Ignace H.J.T.

Abstract

Background: Before 2016, patients with isolated synchronous colorectal peritoneal metastases (PMCRC) diagnosed in expert centers had a higher odds of undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and better overall survival (OS) than those diagnosed in referring centers. Nationwide efforts were initiated to increase awareness and improve referral networks. Methods: This nationwide study aimed to evaluate whether the between-center differences in odds of undergoing CRS-HIPEC and OS have reduced since these national efforts were initiated. All patients with isolated synchronous PMCRC diagnosed between 2009 and 2021 were identified from the Netherlands Cancer Registry. Associations between hospital of diagnosis and the odds of undergoing CRS-HIPEC, as well as OS, were assessed using multilevel multivariable regression analyses for two periods (2009–2015 and 2016–2021). Results: In total, 3948 patients were included. The percentage of patients undergoing CRS-HIPEC increased from 17.2% in 2009–2015 (25.4% in expert centers, 16.5% in referring centers), to 23.4% in 2016–2021 (30.2% in expert centers, 22.6% in referring centers). In 2009–2015, compared with diagnosis in a referring center, diagnosis in a HIPEC center showed a higher odds of undergoing CRS-HIPEC (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.02–2.67) and better survival (hazard ratio [HR] 0.80, 95% CI 0.66–0.96). In 2016–2021, there were no differences in the odds of undergoing CRS-HIPEC between patients diagnosed in HIPEC centers versus referring centers (OR 1.27, 95% CI 0.76–2.13) and survival (HR 1.00, 95% CI 0.76–1.32). Conclusion: Previously observed differences in odds of undergoing CRS-HIPEC were no longer present. Increased awareness and the harmonization of treatment for PMCRC may have contributed to equal access to care and a similar chance of survival at a national

Published
2024

111. An observational cohort of patients with colorectal peritoneal metastases or pseudomyxoma peritonei treated with CRS-HIPEC: Development and first results of the Dutch CRS-HIPEC quality registry

Author

Zorgeenheid Kinderchirurgie Medisch, MS CGO, Cancer, van Erning, Felice N., van den Heuvel, Teun B.M., Sijtsma, Femke P.C., Boerma, Djamila, Brandt-Kerkhof, Alexandra R.M., Bremers, André J., van Duyn, Eino B., van Grevenstein, Helma M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva, de Reuver, Philip R., Wiezer, René J., Witkamp, Arjan J., Nienhuijs, Simon W., Poelmann, Floris B., Tuynman, Jurriaan B., Been, Lucas B., Rovers, Koen P., de Hingh, Ignace H.J.T., Zorgeenheid Kinderchirurgie Medisch, MS CGO, Cancer, van Erning, Felice N., van den Heuvel, Teun B.M., Sijtsma, Femke P.C., Boerma, Djamila, Brandt-Kerkhof, Alexandra R.M., Bremers, André J., van Duyn, Eino B., van Grevenstein, Helma M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva, de Reuver, Philip R., Wiezer, René J., Witkamp, Arjan J., Nienhuijs, Simon W., Poelmann, Floris B., Tuynman, Jurriaan B., Been, Lucas B., Rovers, Koen P., and de Hingh, Ignace H.J.T.

Published
2024

112. Postoperative circadian patterns in wearable sensor measured heart rate: a prospective observational study

Author

Mestrom, Eveline H J, van der Stam, Jonna A, Nienhuijs, Simon W, de Hingh, Ignace H J T, Boer, Arjen-Kars, van Riel, Natal A W, Scharnhorst, Volkher, Bouwman, R Arthur, Mestrom, Eveline H J, van der Stam, Jonna A, Nienhuijs, Simon W, de Hingh, Ignace H J T, Boer, Arjen-Kars, van Riel, Natal A W, Scharnhorst, Volkher, and Bouwman, R Arthur

Abstract

PURPOSE: This study aimed to describe the 24-hour cycle of wearable sensor-obtained heart rate in patients with deterioration-free recovery and to compare it with patients experiencing postoperative deterioration.METHODS: A prospective observational trial was performed in patients following bariatric or major abdominal cancer surgery. A wireless accelerometer patch (Healthdot) continuously measured postoperative heart rate, both in the hospital and after discharge, for a period of 14 days. The circadian pattern, or diurnal rhythm, in the wearable sensor-obtained heart rate was described using peak, nadir and peak-nadir excursions.RESULTS: The study population consisted of 137 bariatric and 100 major abdominal cancer surgery patients. In the latter group, 39 experienced postoperative deterioration. Both surgery types showed disrupted diurnal rhythm on the first postoperative days. Thereafter, the bariatric group had significantly lower peak heart rates (days 4, 7-12, 14), lower nadir heart rates (days 3-14) and larger peak-nadir excursions (days 2, 4-14). In cancer surgery patients, significantly higher nadir (days 2-5) and peak heart rates (days 2-3) were observed prior to deterioration.CONCLUSIONS: The postoperative diurnal rhythm of heart rate is disturbed by different types of surgery. Both groups showed recovery of diurnal rhythm but in patients following cancer surgery, both peak and nadir heart rates were higher than in the bariatric surgery group. Especially nadir heart rate was identified as a potential prognostic marker for deterioration after cancer surgery.

Published
2024

113. Impact of the COVID-19 pandemic on the in-hospital diagnostic pathway of breast and colorectal cancer in the Netherlands: A population-based study

Author

Wolfkamp, Wouter (author), Meijer, Joyce (author), van Hoeve, Jolanda C. (author), van Erning, Felice (author), de Geus-Oei, L.F. (author), de Hingh, Ignace (author), Veltman, Jeroen (author), Siesling, Sabine (author), Wolfkamp, Wouter (author), Meijer, Joyce (author), van Hoeve, Jolanda C. (author), van Erning, Felice (author), de Geus-Oei, L.F. (author), de Hingh, Ignace (author), Veltman, Jeroen (author), and Siesling, Sabine (author)

Abstract

Background: In the Netherlands, the COVID-19 pandemic resulted in a temporary halt of population screening for cancer and limited hospital capacity for non-COVID care. We aimed to investigate the impact of the pandemic on the in-hospital diagnostic pathway of breast cancer (BC) and colorectal cancer (CRC). Methods: 71,159 BC and 48,900 CRC patients were selected from the Netherlands Cancer Registry. Patients, diagnosed between January 2020 and July 2021, were divided into six periods and compared to the average of patients diagnosed in the same periods in 2017–2019. Diagnostic procedures performed were analysed using logistic regression. Lead time of the diagnostic pathway was analysed using Cox regression. Analyses were stratified for cancer type and corrected for age, sex (only CRC), stage and region. Results: For BC, less mammograms were performed during the first recovery period in 2020. More PET-CTs were performed during the first peak, first recovery and third peak period. For CRC, less ultrasounds and more CT scans and MRIs were performed during the first peak. Lead time decreased the most during the first peak by 2 days (BC) and 8 days (CRC). Significantly fewer patients, mainly in lower stages, were diagnosed with BC (−47%) and CRC (−36%) during the first peak. Conclusion: Significant impact of the COVID-19 pandemic was found on the diagnostic pathway, mainly during the first peak. In 2021, care returned to the same standards as before the pandemic. Long-term effects on patient outcomes are not known yet and will be the subject of future research., RST/Radiation, Science and Technology

Published
2024
Full Text
View/download PDF

114. Predicting Long-term Disease-free Survival after Resection of Pancreatic Ductal Adenocarcinoma:A Nationwide Cohort Study

Author

Van Goor, Iris W.J.M., Schouten, Thijs J., Verburg, Daphne N., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., Van Dam, Ronald M., Festen, Sebastiaan, Koerkamp, Bas Groot, Van Der Harst, Erwin, De Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., De Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Verdonk, Robert C., Van Santvoort, Hjalmar C., Daamen, Lois A., Molenaar, I. Quintus, Van Goor, Iris W.J.M., Schouten, Thijs J., Verburg, Daphne N., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., Van Dam, Ronald M., Festen, Sebastiaan, Koerkamp, Bas Groot, Van Der Harst, Erwin, De Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Los, Maartje, Meijer, Gert J., De Meijer, Vincent E., Nieuwenhuijs, Vincent B., Roos, Daphne, Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., Verdonk, Robert C., Van Santvoort, Hjalmar C., Daamen, Lois A., and Molenaar, I. Quintus

Abstract

Objective: To develop a prediction model for long-term (≥5 years) disease-free survival (DFS) after the resection of pancreatic ductal adenocarcinoma (PDAC). Background: Despite high recurrence rates, 10% of patients have long-term DFS after PDAC resection. A model to predict long-term DFS may aid individualized prognostication and shared decision-making. Methods: This nationwide cohort study included all consecutive patients who underwent PDAC resection in the Netherlands (2014-2016). The best-performing prognostic model was selected by Cox-proportional hazard analysis and Akaike's Information Criterion, presented by hazard ratios (HRs) with 95% confidence intervals (CIs). Internal validation was performed, and discrimination and calibration indices were assessed. Results: In all, 836 patients with a median follow-up of 67 months (interquartile range 51-79) were analyzed. Long-term DFS was seen in 118 patients (14%). Factors predictive of long-term DFS were low preoperative carbohydrate antigen 19-9 (logarithmic; HR 1.21; 95% CI 1.10-1.32), no vascular resection (HR 1.33; 95% CI 1.12-1.58), T1 or T2 tumor stage (HR 1.52; 95% CI 1.14-2.04, and HR 1.17; 95% CI 0.98-1.39, respectively), well/moderate tumor differentiation (HR 1.44; 95% CI 1.22-1.68), absence of perineural and lymphovascular invasion (HR 1.42; 95% CI 1.11-1.81 and HR 1.14; 95% CI 0.96-1.36, respectively), N0 or N1 nodal status (HR 1.92; 95% CI 1.54-2.40, and HR 1.33; 95% CI 1.11-1.60, respectively), R0 resection margin status (HR 1.25; 95% CI 1.07-1.46), no major complications (HR 1.14; 95% CI 0.97-1.35) and adjuvant chemotherapy (HR 1.74; 95% CI 1.47-2.06). Moderate performance (concordance index 0.68) with adequate calibration (slope 0.99) was achieved. Conclusions: The developed prediction model, readily available at www.pancreascalculator.com, can be used to estimate the probability of long-term D

Published
2024

115. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases:Protocol of the multicentre, open-label, phase II, INTERACT-II trial

Author

Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., Burger, Jacobus W.A., Van De Vlasakker, Vincent C.J., Guchelaar, Niels A.D., Van Den Heuvel, Teun B.M., Lurvink, Robin J., Van Meerten, Esther, Bax, Ramon J.F., Creemers, Geert Jan M., Van Hellemond, Irene E.G., Brandt-Kerkhof, Alexandra R.M., Madsen, Eva V.E., Nederend, Joost, Koolen, Stijn L.W., Nienhuijs, Simon W., Kranenburg, Onno, De Hingh, Ignace H.J.T., Verhoef, Cornelis, Mathijssen, Ron H.J., and Burger, Jacobus W.A.

Abstract

Introduction:The peritoneum is the second most affected organ for the dissemination of colorectal cancer (CRC). Patients with colorectal peritoneal metastases (CPM) face a poor prognosis, despite the majority of patients being treated with palliative systemic therapy. The efficacy of palliative systemic therapy is limited due to the plasma-peritoneum barrier. The poor prognosis of unresectable CPM patients has resulted in the development of new treatment strategies where systemic therapy is combined with local, intraperitoneal chemotherapy. In the recently published phase I study, the maximum tolerated dose and thus the recommended phase II dose of intraperitoneal irinotecan was investigated and determined to be 75 mg. In the present study, the overall survival after treatment with 75 mg irinotecan with concomitant mFOLFOX4 and bevacizumab will be investigated. Materials and methods:In this single-arm phase II study in two Dutch tertiary referral centres, 85 patients are enrolled. Eligibility criteria are an adequate performance status and organ function, histologically confirmed microsatellite stable and unresectable CPM, no previous palliative therapy for CRC, no systemic therapy<6 months for CRC prior to enrolment and no previous cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC). Patients will undergo a diagnostic laparoscopy as standard work-up for CPM and if the peritoneal disease is considered unresectable (eg, Peritoneal Cancer Index (PCI)>20, too extensive small bowel involvement), a peritoneal access port and a port-a-cath are placed for administration of intraperitoneal and intravenous chemotherapy, respectively. Patients may undergo up to 12 cycles of study treatment. Each cycle consists of intravenous mFOLFOX4 with bevacizumab and concomitant intraperitoneal irinotecan (75 mg), which is repeated every 2 weeks, with a maximum of 12 cycles. Modified FOLFOX-4 regimen consists of 8

Published
2024

116. Towards Equal Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Survival in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study

Author

MS CGO, Cancer, van der Ven, Roos G.F.M., van den Heuvel, Teun B.M., Rovers, Koen P.B., Nienhuijs, Simon W., Boerma, Djamila, van Grevenstein, Wilhelmina M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva V.E., de Reuver, Philip, Tuynman, Jurriaan B., van Erning, Felice N., de Hingh, Ignace H.J.T., MS CGO, Cancer, van der Ven, Roos G.F.M., van den Heuvel, Teun B.M., Rovers, Koen P.B., Nienhuijs, Simon W., Boerma, Djamila, van Grevenstein, Wilhelmina M.U., Hemmer, Patrick H.J., Kok, Niels F.M., Madsen, Eva V.E., de Reuver, Philip, Tuynman, Jurriaan B., van Erning, Felice N., and de Hingh, Ignace H.J.T.

Published
2024

117. Early experience with robotic pancreatoduodenectomy versus open pancreatoduodenectomy: nationwide propensity-score-matched analysis

Author

MS HOD, Cancer, MS CGO, de Graaf, Nine, Zwart, Maurice J.W., van Hilst, Jony, van den Broek, Bram, Bonsing, Bert A., Busch, Olivier R., Coene, Peter Paul L.O., Daams, Freek, van Dieren, Susan, van Eijck, Casper H.J., Festen, Sebastiaan, de Hingh, Ignace H.J.T., Lips, Daan J., Luyer, Misha D.P., Mieog, J. Sven D., van Santvoort, Hjalmar C., van der Schelling, George P., Stommel, Martijn W.J., de Wilde, Roeland F., Molenaar, I. Quintus, Koerkamp, Bas Groot, Besselink, Marc G., MS HOD, Cancer, MS CGO, de Graaf, Nine, Zwart, Maurice J.W., van Hilst, Jony, van den Broek, Bram, Bonsing, Bert A., Busch, Olivier R., Coene, Peter Paul L.O., Daams, Freek, van Dieren, Susan, van Eijck, Casper H.J., Festen, Sebastiaan, de Hingh, Ignace H.J.T., Lips, Daan J., Luyer, Misha D.P., Mieog, J. Sven D., van Santvoort, Hjalmar C., van der Schelling, George P., Stommel, Martijn W.J., de Wilde, Roeland F., Molenaar, I. Quintus, Koerkamp, Bas Groot, and Besselink, Marc G.

Published
2024

118. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial

Author

MS Gynaecologische Oncologie, Cancer, Aronson, S. Lot, Lopez-Yurda, Marta, Koole, Simone N., Schagen Van Leeuwen, Jules H., Schreuder, Hendrik W.R., Hermans, Ralph H.M., De Hingh, Ignace H.J.T., Van Gent, Mignon D.J.M., Arts, Henriëtte J.G., Van Ham, Maaike A.P.C., Van Dam, Peter A., Vuylsteke, Peter, Aalbers, Arend G.J., Verwaal, Victor J., Van De Vijver, Koen K., Aaronson, Neil K., Sonke, Gabe S., Van Driel, Willemien J., MS Gynaecologische Oncologie, Cancer, Aronson, S. Lot, Lopez-Yurda, Marta, Koole, Simone N., Schagen Van Leeuwen, Jules H., Schreuder, Hendrik W.R., Hermans, Ralph H.M., De Hingh, Ignace H.J.T., Van Gent, Mignon D.J.M., Arts, Henriëtte J.G., Van Ham, Maaike A.P.C., Van Dam, Peter A., Vuylsteke, Peter, Aalbers, Arend G.J., Verwaal, Victor J., Van De Vijver, Koen K., Aaronson, Neil K., Sonke, Gabe S., and Van Driel, Willemien J.

Published
2024

119. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy

Author

Cancer, MS CGO, MS HOD, Stoop, Thomas F., Seelen, Leonard W.F., van ’t Land, Freek R., Lutchman, Kishan R.D., van Dieren, Susan, Lips, Daan J., van der Harst, Erwin, Kazemier, Geert, Patijn, Gijs A., de Hingh, Ignace H., Wijsman, Jan H., Erdmann, Joris I., Festen, Sebastiaan, Groot Koerkamp, Bas, Mieog, J. Sven D., den Dulk, Marcel, Stommel, Martijn W.J., Busch, Olivier R., de Wilde, Roeland F., de Meijer, Vincent E., te Riele, Wouter, Molenaar, I. Quintus, van Eijck, Casper H.J., van Santvoort, Hjalmar C., Besselink, Marc G., Cancer, MS CGO, MS HOD, Stoop, Thomas F., Seelen, Leonard W.F., van ’t Land, Freek R., Lutchman, Kishan R.D., van Dieren, Susan, Lips, Daan J., van der Harst, Erwin, Kazemier, Geert, Patijn, Gijs A., de Hingh, Ignace H., Wijsman, Jan H., Erdmann, Joris I., Festen, Sebastiaan, Groot Koerkamp, Bas, Mieog, J. Sven D., den Dulk, Marcel, Stommel, Martijn W.J., Busch, Olivier R., de Wilde, Roeland F., de Meijer, Vincent E., te Riele, Wouter, Molenaar, I. Quintus, van Eijck, Casper H.J., van Santvoort, Hjalmar C., and Besselink, Marc G.

Published
2024

120. The impact of hospital experience in bariatric surgery on short-term outcomes after minimally invasive esophagectomy: a nationwide analysis

Author

MS CGO, Cancer, Janssen, Henricus J B, Geraedts, Tessa C M, Simkens, Geert A, Visser, Maurits, de Hingh, Ignace H J T, van Det, Marc J, Nieuwenhuijzen, Grard A P, van Hillegersberg, Richard, Luyer, Misha D P, Nienhuijs, Simon W, MS CGO, Cancer, Janssen, Henricus J B, Geraedts, Tessa C M, Simkens, Geert A, Visser, Maurits, de Hingh, Ignace H J T, van Det, Marc J, Nieuwenhuijzen, Grard A P, van Hillegersberg, Richard, Luyer, Misha D P, and Nienhuijs, Simon W

Published
2024

121. Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to Five Years after Diagnosis

Author

Smit, Karel C., Derksen, Jeroen W.G., Stellato, Rebecca K., van Lanen, Anne-Sophie, Wesselink, Evertine, Belt, Eric J.T., Cloos-van Balen, Marissa, Coene, Peter Paul L.O., Dekker, Jan Willem T., de Groot, Jan Willem, Haringhuizen, Annebeth W., van Halteren, Henk K., van Heek, Tjarda T., Helgason, Helgi H., Hendriks, Mathijs P., de Hingh, Ignace H.J.T., Hoekstra, Ronald, Houtsma, Danny, Janssen, Johan J.B., Kok, Niels, Konsten, Joop L.M., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J.M., Peeters, Koen C.M.J., Polée, Marco B., Rietbroek, Ron C., Schiphorst, Anandi H.W., Schrauwen, Ruud W.M., Schreinemakers, Jennifer, Sie, Mark P.S., Simkens, Lieke, Sonneveld, Eric J.A., Terheggen, Frederiek, Valkenburg-van Iersel, Liselot, Vles, Wouter J., Wasowicz-Kemps, Daria K., de Wilt, Johannes H.W., Kok, Dieuwertje E., Winkels, Renate M., Kampman, Ellen, van Duijnhoven, Fränzel J.B., Koopman, Miriam, May, Anne M., Smit, Karel C., Derksen, Jeroen W.G., Stellato, Rebecca K., van Lanen, Anne-Sophie, Wesselink, Evertine, Belt, Eric J.T., Cloos-van Balen, Marissa, Coene, Peter Paul L.O., Dekker, Jan Willem T., de Groot, Jan Willem, Haringhuizen, Annebeth W., van Halteren, Henk K., van Heek, Tjarda T., Helgason, Helgi H., Hendriks, Mathijs P., de Hingh, Ignace H.J.T., Hoekstra, Ronald, Houtsma, Danny, Janssen, Johan J.B., Kok, Niels, Konsten, Joop L.M., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J.M., Peeters, Koen C.M.J., Polée, Marco B., Rietbroek, Ron C., Schiphorst, Anandi H.W., Schrauwen, Ruud W.M., Schreinemakers, Jennifer, Sie, Mark P.S., Simkens, Lieke, Sonneveld, Eric J.A., Terheggen, Frederiek, Valkenburg-van Iersel, Liselot, Vles, Wouter J., Wasowicz-Kemps, Daria K., de Wilt, Johannes H.W., Kok, Dieuwertje E., Winkels, Renate M., Kampman, Ellen, van Duijnhoven, Fränzel J.B., Koopman, Miriam, and May, Anne M.

Abstract

Introduction: Physical activity (PA) is associated with higher quality of life and probably better prognosis among colorectal cancer (CRC) patients. This study focuses on determinants of PA among CRC patients from diagnosis until five years post-diagnosis.Methods: Sociodemographic and disease-related factors of participants of two large CRC cohort studies were combined. Moderate-to-vigorous PA during sport and leisure time (MVPA-SL) was measured at diagnosis (T0) and six, twelve, twenty-four, and sixty (T6 to T60) months post-diagnosis, using the SQUASH questionnaire. Mixed-effects models were performed to identify sociodemographic and disease-related determinants of MVPA-SL, separately for stage I-III colon (CC), stage I-III rectal cancer (RC), and stage IV CRC (T0 and T6 only). Associations were defined as consistently present when significant at ≥4 timepoints for the stage I-III subsets. MVPA-SL levels were compared with an age- and sex-matched sample of the general Dutch population.Results: In total, 2905 CC, 1459 RC and 436 stage IV CRC patients were included. Patients with higher fatigue scores, and women compared to men had consistently lower MVPA-SL levels over time, regardless of tumor type and stage. At T6, having a stoma was significantly associated with lower MVPA-SL among stage I-III RC patients. Systemic therapy and radiotherapy were not significantly associated with MVPA-SL changes at T6. Compared to the general population, MVPA-SL levels of CRC patients were lower at all timepoints, most notably at T6.Conclusions: Female sex and higher fatigue scores were consistent determinants of lower MVPA-SL levels among all CRC patients, and MVPA-SL levels were lowest at six months post-diagnosis. Our results can inform the design of intervention studies aimed at improving PA, and guide healthcare professionals in optimizing individualized support.

Published
2024

122. Development of a Supramolecular Hydrogel for Intraperitoneal Injections

Author

Wintjens, Anne G.W.E., Fransen, Peter-Paul K.H., Lenaerts, Kaatje, Liu, Hong, van Almen, Geert C., van Steensel, Sebastiaan, Gijbels, Marion J., de Hingh, Ignace H.J.T., Dankers, Patricia Y.W., Bouvy, Nicole D., Wintjens, Anne G.W.E., Fransen, Peter-Paul K.H., Lenaerts, Kaatje, Liu, Hong, van Almen, Geert C., van Steensel, Sebastiaan, Gijbels, Marion J., de Hingh, Ignace H.J.T., Dankers, Patricia Y.W., and Bouvy, Nicole D.

Abstract

Local intraperitoneal drug administration is considered a challenging drug delivery route. The therapeutic efficiency is low, mainly due to rapid clearance of drugs. To increase the intraperitoneal retention time of specific drugs, a pH-sensitive supramolecular hydrogel that can act as a drug delivery vehicle is developed. To establish the optimal formulation of the hydrogel and to study its feasibility, safety, and tissue compatibility, in vitro, postmortem, and in vivo experiments are performed. In vitro tests reveal that a hydrogelator formulation with pH ≥ 9 results in a constant viscosity of 0.1 Pa·s. After administration postmortem, the hydrogel covers the parietal and visceral peritoneum with a thin, soft layer. In the subsequent in vivo experiments, 14 healthy rats are subjected to intraperitoneal injection with the hydrogel. Fourteen and 28 days after implantation, the animals are euthanized. Intraperitoneal exposure to the hydrogel is not resulted in significant weight loss or discomfort. Moreover, no macroscopic adverse effects or signs of organ damage are detected. In several intra-abdominal tissues, vacuolated macrophages are found indicating a physiological degradation of the synthetic hydrogel. This study demonstrates that the supramolecular hydrogel is safe for intraperitoneal application and that the hydrogel shows good tissue compatibility in rats.

Published
2024

123. Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Author

Dietz, Michelle V, Hannink, Gerjon, Said, Ibrahim, van der Zant, Femke A, van de Vlasakker, Vincent C J, Brandt-Kerkhof, Alexandra R M, Verhoef, Cornelis, Bremers, Andreas J A, de Wilt, Johannes H W, Hemmer, Patrick H J, de Hingh, Ignace H J T, de Reuver, Philip R, Madsen, Eva V E, Dietz, Michelle V, Hannink, Gerjon, Said, Ibrahim, van der Zant, Femke A, van de Vlasakker, Vincent C J, Brandt-Kerkhof, Alexandra R M, Verhoef, Cornelis, Bremers, Andreas J A, de Wilt, Johannes H W, Hemmer, Patrick H J, de Hingh, Ignace H J T, de Reuver, Philip R, and Madsen, Eva V E

Abstract

INTRODUCTION: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival outcomes for selected patients with colorectal peritoneal metastases (PM), but recurrence rates are high. The aim of this study was to develop a tool to predict recurrence in patients with colorectal PM that undergo CRS-HIPEC.MATERIALS AND METHODS: For this retrospective cohort study, data of patients that underwent CRS-HIPEC for colorectal PM from four Dutch HIPEC centers were used. Exclusion criteria were perioperative systemic therapy and peritoneal cancer index (PCI) ≥20. Nine previously identified factors were considered as predictors: gender, age, primary tumor characteristics (location, nodal stage, differentiation, and mutation status), synchronous liver metastases, preoperative Carcino-Embryonal Antigen (CEA), and peritoneal cancer index (PCI). The prediction model was developed using multivariable Cox regression and validated internally using bootstrapping. The performance of the model was evaluated by discrimination and calibration.RESULTS: In total, 408 patients were included. During the follow-up, recurrence of disease occurred in 318 patients (78%). Significant predictors of recurrence were PCI (HR 1.075, 95% CI 1.044-1.108) and primary tumor location (left sided HR 0.719, 95% CI 0.550-0.939). The prediction model for recurrence showed fair discrimination with a C-index of 0.64 (95% CI 0.62, 0.66) after internal validation. The model was well-calibrated with good agreement between the predicted and observed probabilities.CONCLUSION: We developed a prediction tool that could aid in the prediction of recurrence in patients with colorectal PM who undergo CRS-HIPEC.

Published
2024

124. Early experience with robotic pancreatoduodenectomy versus open pancreatoduodenectomy:nationwide propensity-score-matched analysis

Author

de Graaf, Nine, Zwart, Maurice J.W., van Hilst, Jony, van den Broek, Bram, Bonsing, Bert A., Busch, Olivier R., Coene, Peter Paul L.O., Daams, Freek, van Dieren, Susan, van Eijck, Casper H.J., Festen, Sebastiaan, de Hingh, Ignace H.J.T., Lips, Daan J., Luyer, Misha D.P., Mieog, J. Sven D., van Santvoort, Hjalmar C., van der Schelling, George P., Stommel, Martijn W.J., de Wilde, Roeland F., Molenaar, I. Quintus, Koerkamp, Bas Groot, Besselink, Marc G., de Graaf, Nine, Zwart, Maurice J.W., van Hilst, Jony, van den Broek, Bram, Bonsing, Bert A., Busch, Olivier R., Coene, Peter Paul L.O., Daams, Freek, van Dieren, Susan, van Eijck, Casper H.J., Festen, Sebastiaan, de Hingh, Ignace H.J.T., Lips, Daan J., Luyer, Misha D.P., Mieog, J. Sven D., van Santvoort, Hjalmar C., van der Schelling, George P., Stommel, Martijn W.J., de Wilde, Roeland F., Molenaar, I. Quintus, Koerkamp, Bas Groot, and Besselink, Marc G.

Abstract

Background: Although robotic pancreatoduodenectomy has shown promising outcomes in experienced high-volume centres, it is unclear whether implementation on a nationwide scale is safe and beneficial. The aim of this study was to compare the outcomes of the early experience with robotic pancreatoduodenectomy versus open pancreatoduodenectomy in the Netherlands. Methods: This was a nationwide retrospective cohort study of all consecutive patients who underwent robotic pancreatoduodenectomy or open pancreatoduodenectomy who were registered in the mandatory Dutch Pancreatic Cancer Audit (18 centres, 2014-2021), starting from the first robotic pancreatoduodenectomy procedure per centre. The main endpoints were major complications (Clavien-Dindo grade greater than or equal to III) and in-hospital/30-day mortality. Propensity-score matching (1 : 1) was used to minimize selection bias. Results: Overall, 701 patients who underwent robotic pancreatoduodenectomy and 4447 patients who underwent open pancreatoduodenectomy were included. Among the eight centres that performed robotic pancreatoduodenectomy, the median robotic pancreatoduodenectomy experience was 86 (range 48-149), with a 7.3% conversion rate. After matching (698 robotic pancreatoduodenectomy patients versus 698 open pancreatoduodenectomy control patients), no significant differences were found in major complications (40.3% versus 36.2% respectively; P = 0.186), in-hospital/30-day mortality (4.0% versus 3.1% respectively; P = 0.326), and postoperative pancreatic fistula grade B/C (24.9% versus 23.5% respectively; P = 0.578). Robotic pancreatoduodenectomy was associated with a longer operating time (359 min versus 301 min; P < 0.001), less intraoperative blood loss (200 ml versus 500 ml; P < 0.001), fewer wound infections (7.4% versus 12.2%; P = 0.008), and a shorter hospital stay (11 days versus 12 days; P < 0.001). Centres performing greater than or equal to 20 robotic pancreatoduodenectomies annually h

Published
2024

125. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancreatic ductal adenocarcinoma:a nationwide analysis

Author

Wismans, Leonoor V., Suurmeijer, J. Annelie, van Dongen, Jelle C., Bonsing, Bert A., Van Santvoort, Hjalmar C., Wilmink, Johanna W., van Tienhoven, Geertjan, de Hingh, Ignace H., Lips, Daan J., van der Harst, Erwin, de Meijer, Vincent E., Patijn, Gijs A., Bosscha, Koop, Stommel, Martijn W., Festen, Sebastiaan, den Dulk, Marcel, Nuyttens, Joost J., Intven, Martijn P.W., de Vos-Geelen, Judith, Molenaar, I. Quintus, Busch, Olivier R., Koerkamp, Bas Groot, Besselink, Marc G., van Eijck, Casper H.J., Wismans, Leonoor V., Suurmeijer, J. Annelie, van Dongen, Jelle C., Bonsing, Bert A., Van Santvoort, Hjalmar C., Wilmink, Johanna W., van Tienhoven, Geertjan, de Hingh, Ignace H., Lips, Daan J., van der Harst, Erwin, de Meijer, Vincent E., Patijn, Gijs A., Bosscha, Koop, Stommel, Martijn W., Festen, Sebastiaan, den Dulk, Marcel, Nuyttens, Joost J., Intven, Martijn P.W., de Vos-Geelen, Judith, Molenaar, I. Quintus, Busch, Olivier R., Koerkamp, Bas Groot, Besselink, Marc G., and van Eijck, Casper H.J.

Abstract

Background: Postoperative pancreatic fistula remains the leading cause of significant morbidity after pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Preoperative chemoradiotherapy has been described to reduce the risk of postoperative pancreatic fistula, but randomized trials on neoadjuvant treatment in pancreatic ductal adenocarcinoma focus increasingly on preoperative chemotherapy rather than preoperative chemoradiotherapy. This study aimed to investigate the impact of preoperative chemotherapy and preoperative chemoradiotherapy on postoperative pancreatic fistula and other pancreatic-specific surgery related complications on a nationwide level. Methods: All patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included in the mandatory nationwide prospective Dutch Pancreatic Cancer Audit (2014–2020). Baseline and treatment characteristics were compared between immediate surgery, preoperative chemotherapy, and preoperative chemoradiotherapy. The relationship between preoperative chemotherapy, chemoradiotherapy, and clinically relevant postoperative pancreatic fistula (International Study Group of Pancreatic Surgery grade B/C) was investigated using multivariable logistic regression analyses. Results: Overall, 2,019 patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included, of whom 1,678 underwent immediate surgery (83.1%), 192 (9.5%) received preoperative chemotherapy, and 149 (7.4%) received preoperative chemoradiotherapy. Postoperative pancreatic fistula occurred in 8.3% of patients after immediate surgery, 4.2% after preoperative chemotherapy, and 2.0% after preoperative chemoradiotherapy (P = .004). In multivariable analysis, the use of preoperative chemoradiotherapy was associated with reduced risk of postoperative pancreatic fistula (odds ratio, 0.21; 95% confidence interval, 0.03–0.69; P = .033) compared with immediate surgery, whereas preoperative chemotherapy was not (odds ratio, 0.59

Published
2024

126. Robot-assisted versus laparoscopic pancreatoduodenectomy:a pan-European multicenter propensity-matched study

Author

Emmen, Anouk M.L.H., Zwart, Maurice J.W., Khatkov, Igor E., Boggi, Ugo, Groot Koerkamp, Bas, Busch, Olivier R., Saint-Marc, Olivier, Dokmak, Safi, Molenaar, I. Quintus, D'Hondt, Mathieu, Ramera, Marco, Keck, Tobias, Ferrari, Giovanni, Luyer, Misha D.P., Moraldi, Luca, Ielpo, Benedetto, Wittel, Uwe, Souche, Francois Regis, Hackert, Thilo, Lips, Daan, Can, Mehmet Fatih, Bosscha, Koop, Fara, Regis, Festen, Sebastiaan, van Dieren, Susan, Coratti, Andrea, De Hingh, Ignace, Mazzola, Michele, Wellner, Ulrich, De Meyere, Celine, van Santvoort, Hjalmar C., Aussilhou, Béatrice, Ibenkhayat, Abdallah, de Wilde, Roeland F., Kauffmann, Emanuele F., Tyutyunnik, Pavel, Besselink, Marc G., Abu Hilal, Mohammad, Manzoni, Alberto, Guerra, Martina, Daams, Freek, Kazemier, Geert, Izrailov, Roman, Efanov, Mikhail, Napoli, Niccolò, Ginesini, Michael, Cappelle, Marie, Haen, Roel, Quetel, Romain, Pucci, Marco, Emmen, Anouk M.L.H., Zwart, Maurice J.W., Khatkov, Igor E., Boggi, Ugo, Groot Koerkamp, Bas, Busch, Olivier R., Saint-Marc, Olivier, Dokmak, Safi, Molenaar, I. Quintus, D'Hondt, Mathieu, Ramera, Marco, Keck, Tobias, Ferrari, Giovanni, Luyer, Misha D.P., Moraldi, Luca, Ielpo, Benedetto, Wittel, Uwe, Souche, Francois Regis, Hackert, Thilo, Lips, Daan, Can, Mehmet Fatih, Bosscha, Koop, Fara, Regis, Festen, Sebastiaan, van Dieren, Susan, Coratti, Andrea, De Hingh, Ignace, Mazzola, Michele, Wellner, Ulrich, De Meyere, Celine, van Santvoort, Hjalmar C., Aussilhou, Béatrice, Ibenkhayat, Abdallah, de Wilde, Roeland F., Kauffmann, Emanuele F., Tyutyunnik, Pavel, Besselink, Marc G., Abu Hilal, Mohammad, Manzoni, Alberto, Guerra, Martina, Daams, Freek, Kazemier, Geert, Izrailov, Roman, Efanov, Mikhail, Napoli, Niccolò, Ginesini, Michael, Cappelle, Marie, Haen, Roel, Quetel, Romain, and Pucci, Marco

Abstract

Background: The use of robot-assisted and laparoscopic pancreatoduodenectomy is increasing, yet large adjusted analyses that can be generalized internationally are lacking. This study aimed to compare outcomes after robot-assisted pancreatoduodenectomy and laparoscopic pancreatoduodenectomy in a pan-European cohort. Methods: An international multicenter retrospective study including patients after robot-assisted pancreatoduodenectomy and laparoscopic pancreatoduodenectomy from 50 centers in 12 European countries (2009–2020). Propensity score matching was performed in a 1:1 ratio. The primary outcome was major morbidity (Clavien–Dindo ≥III). Results: Among 2,082 patients undergoing minimally invasive pancreatoduodenectomy, 1,006 underwent robot-assisted pancreatoduodenectomy and 1,076 laparoscopic pancreatoduodenectomy. After matching 812 versus 812 patients, the rates of major morbidity (31.9% vs 29.6%; P = .347) and 30-day/in-hospital mortality (4.3% vs 4.6%; P = .904) did not differ significantly between robot-assisted pancreatoduodenectomy and laparoscopic pancreatoduodenectomy, respectively. Robot-assisted pancreatoduodenectomy was associated with a lower conversion rate (6.7% vs 18.0%; P < .001) and higher lymph node retrieval (16 vs 14; P = .003). Laparoscopic pancreatoduodenectomy was associated with shorter operation time (446 minutes versus 400 minutes; P < .001), and lower rates of postoperative pancreatic fistula grade B/C (19.0% vs 11.7%; P < .001), delayed gastric emptying grade B/C (21.4% vs 7.4%; P < .001), and a higher R0-resection rate (73.2% vs 84.4%; P < .001). Conclusion: This European multicenter study found no differences in overall major morbidity and 30-day/in-hospital mortality after robot-assisted pancreatoduodenectomy compared with laparoscopic pancreatoduodenectomy. Further, laparoscopic pancreatoduodenectomy was associated with a lower rate of

Published
2024

127. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection:A Nationwide Analysis

Author

Schouten, Thijs J., van Goor, Iris W.J.M., Dorland, Galina A., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Liem, Mike S.L., van Lienden, Krijn P., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., van Tienhoven, Geert Jan, Verdonk, Robert C., Verkooijen, Helena M., van Santvoort, Hjalmar C., Molenaar, I. Quintus, Daamen, Lois A., Schouten, Thijs J., van Goor, Iris W.J.M., Dorland, Galina A., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A.A., Busch, Olivier R., Cirkel, Geert A., van Dam, Ronald M., Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H.J.T., Intven, Martijn P.W., Kazemier, Geert, Liem, Mike S.L., van Lienden, Krijn P., Los, Maartje, de Meijer, Vincent E., Patijn, Gijs A., Schreinemakers, Jennifer M.J., Stommel, Martijn W.J., van Tienhoven, Geert Jan, Verdonk, Robert C., Verkooijen, Helena M., van Santvoort, Hjalmar C., Molenaar, I. Quintus, and Daamen, Lois A.

Abstract

Background: Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond anatomical criteria, considering both biological and conditional factors. This has, however, yet to be validated on a nationwide scale. This study evaluated the prognostic value of biological and conditional factors for staging of patients with resectable PDAC. Patients and Methods: A nationwide observational cohort study was performed, including all consecutive patients who underwent upfront resection of National Comprehensive Cancer Network resectable PDAC in the Netherlands (2014–2019) with complete information on preoperative carbohydrate antigen (CA) 19-9 and Eastern Cooperative Oncology Group (ECOG) performance status. PDAC was considered biologically unfavorable (RB+) if CA19-9 ≥ 500 U/mL and favorable (RB−) otherwise. ECOG ≥ 2 was considered conditionally unfavorable (RC+) and favorable otherwise (RC−). Overall survival (OS) was assessed using Kaplan–Meier and Cox-proportional hazard analysis, presented as hazard ratios (HRs) with 95% confidence interval (CI). Results: Overall, 688 patients were analyzed with a median overall survival (OS) of 20 months (95% CI 19–23). OS was 14 months (95% CI 10 months—median not reached) in 20 RB+C+ patients (3%; HR 1.61, 95% CI 0.86–2.70), 13 months (95% CI 11–15) in 156 RB+C− patients (23%; HR 1.86, 95% CI 1.50–2.31), and 21 months (95% CI 12–41) in 47 RB−C+ patients (7%; HR 1.14, 95% CI 0.80–1.62) compared with 24 months (95% CI 22–27) in 465 patients with RB−C− PDAC (68%; reference). Conclusions: Survival after upfront resection of anatomically resectable PDAC is worse in patients with CA19-9 ≥ 500 U/mL, while performance status had no impact. This supports consideration of CA19-9 in preoperative staging of resectable PDAC.

Published
2024

128. Outcomes of a Multicenter Training Program in Robotic Pancreatoduodenectomy (LAELAPS-3)

Author

Zwart, Maurice J.W., Nota, Carolijn L.M., de Rooij, Thijs, van Hilst, Jony, te Riele, Wouter W., van Santvoort, Hjalmar C., Hagendoorn, Jeroen, Borei Rinkes, Inne H.M., van Dam, Jacob L., Latenstein, Anouk E.J., Takagi, Kosei, Tran, Khé T.C., Schreinemakers, Jennifer, van der Schelling, George P., Wijsman, Jan H., Festen, Sebastiaan, Daams, Freek, Luyer, Misha D., de Hingh, Ignace H.J.T., Mieog, Jan S.D., Bonsing, Bert A., Lips, Daan J., Hilal, Mohammed Abu, Busch, Olivier R., Saint-Marc, Olivier, Zehl, Herbert J., II, Zureikat, Amer H., Hogg, Melissa E., Molenaar, I. Quintus, Besselink, Marc G., and Koerkamp, Bas Groot

Published
2022
Full Text
View/download PDF

129. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer

Author

Schouten, Thijs J., Daamen, Lois A., Dorland, Galina, van Roessel, Stijn R., Groot, Vincent P., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A. A., Busch, Olivier R., van Dam, Ronald M., Fariña Sarasqueta, Arantza, Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H. J. T., Intven, Martijn, Kazemier, Geert, de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Raicu, G. Mihaela, Roos, Daphne, Schreinemakers, Jennifer M. J., Stommel, Martijn W. J., van Velthuysen, M. F., Verdonk, Robert C., Verheij, Joanne, Verkooijen, Helena M., van Santvoort, Hjalmar C., and Molenaar, I. Quintus

Published
2022
Full Text
View/download PDF

132. Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up

Author

Mackay, Tara M., Latenstein, Anouk E.J., Bonsing, Bert A., Bruno, Marco J., van Eijck, Casper H.J., Groot Koerkamp, Bas, de Hingh, Ignace H.J.T., Homs, Marjolein Y.V., van Hooft, Jeanin E., van Laarhoven, Hanneke W., Molenaar, I. Quintus, van Santvoort, Hjalmar C., Stommel, Martijn W.J., de Vos-Geelen, Judith, Wilmink, Johanna W., Busch, Olivier R., van der Geest, Lydia G., and Besselink, Marc G.

Published
2020
Full Text
View/download PDF

134. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative Prediction Model

Author

Walma, Marieke, primary, Maggino, Laura, additional, Smits, F. Jasmijn, additional, Borggreve, Alicia S., additional, Daamen, Lois A., additional, Groot, Vincent P., additional, Casciani, Fabio, additional, de Meijer, Vincent E., additional, Wessels, Frank J., additional, van der Schelling, George P., additional, Nieuwenhuijs, Vincent B., additional, Bosscha, Koop, additional, van der Harst, Erwin van der, additional, van Dam, Ronald van, additional, Liem, Mike S., additional, Festen, Sebastiaan, additional, Stommel, Martijn W. J., additional, Roos, Daphne, additional, Wit, Fennie, additional, de Hingh, Ignace H. de, additional, Bonsing, Bert A., additional, Busch, Olivier R., additional, Groot Koerkamp, Bas, additional, Kazemier, Geert, additional, Besselink, Marc G., additional, Salvia, Roberto, additional, Malleo, Giuseppe, additional, Molenaar, I. Quintus, additional, and van Santvoort, Hjalmar C., additional

Published
2024
Full Text
View/download PDF

136. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial

Author

Aronson, S. Lot, primary, Lopez-Yurda, Marta, additional, Koole, Simone N., additional, Schagen van Leeuwen, Jules H., additional, Schreuder, Hendrik W.R., additional, Hermans, Ralph H.M., additional, de Hingh, Ignace H.J.T., additional, van Gent, Mignon D.J.M., additional, Arts, Henriëtte J.G., additional, van Ham, Maaike A.P.C., additional, van Dam, Peter A., additional, Vuylsteke, Peter, additional, Aalbers, Arend G.J., additional, Verwaal, Victor J., additional, Van de Vijver, Koen K., additional, Aaronson, Neil K., additional, Sonke, Gabe S., additional, and van Driel, Willemien J., additional

Published
2024
Full Text
View/download PDF

137. Early experience with robotic pancreatoduodenectomy versus open pancreatoduodenectomy: nationwide propensity-score-matched analysis

Author

de Graaf, Nine, primary, Zwart, Maurice J W, additional, van Hilst, Jony, additional, van den Broek, Bram, additional, Bonsing, Bert A, additional, Busch, Olivier R, additional, Coene, Peter-Paul L O, additional, Daams, Freek, additional, van Dieren, Susan, additional, van Eijck, Casper H J, additional, Festen, Sebastiaan, additional, de Hingh, Ignace H J T, additional, Lips, Daan J, additional, Luyer, Misha D P, additional, Mieog, J Sven D, additional, van Santvoort, Hjalmar C, additional, van der Schelling, George P, additional, Stommel, Martijn W J, additional, de Wilde, Roeland F, additional, Molenaar, I Quintus, additional, Groot Koerkamp, Bas, additional, and Besselink, Marc G, additional

Published
2024
Full Text
View/download PDF

138. Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial

Author

Lurvink, Robin J., Tajzai, Rudaba, Rovers, Koen P., Wassenaar, Emma C. E., Moes, Dirk-Jan A. R., Pluimakers, Giulia, Boerma, Djamila, Burger, Jacobus W. A., Nienhuijs, Simon W., de Hingh, Ignace H. J. T., and Deenen, Maarten J.

Published
2021
Full Text
View/download PDF

139. ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer

Author

Schouten, Thijs J., Daamen, Lois A., Dorland, Galina, van Roessel, Stijn R., Groot, Vincent P., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Brosens, Lodewijk A. A., Busch, Olivier R., van Dam, Ronald M., Fariña Sarasqueta, Arantza, Festen, Sebastiaan, Groot Koerkamp, Bas, van der Harst, Erwin, de Hingh, Ignace H. J. T., Intven, Martijn, Kazemier, Geert, de Meijer, Vincent E., Nieuwenhuijs, Vincent B., Raicu, G. Mihaela, Roos, Daphne, Schreinemakers, Jennifer M. J., Stommel, Martijn W. J., van Velthuysen, M. F., Verdonk, Robert C., Verheij, Joanne, Verkooijen, Helena M., van Santvoort, Hjalmar C., and Molenaar, I. Quintus

Published
2022
Full Text
View/download PDF

141. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Patients

Author

Versteijne, Eva, Suker, Mustafa, Groen, Jesse V., Besselink, Marc G., Bonsing, Bert A., Bosscha, Koop, Busch, Olivier R., de Hingh, Ignace H. J. T., de Jong, Koert P., Molenaar, I. Quintus, van Santvoort, Hjalmar C., Verkooijen, Helena M., Van Eijck, Casper H., and van Tienhoven, Geertjan

Published
2022
Full Text
View/download PDF

142. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)

Author

van Dongen, Jelle C., Suker, Mustafa, Versteijne, Eva, Bonsing, Bert A., Mieog, J. Sven D., de Vos-Geelen, Judith, van der Harst, Erwin, Patijn, Gijs A., de Hingh, Ignace H., Festen, Sebastiaan, Ten Tije, Albert J., Busch, Olivier R., Besselink, Marc G., van Tienhoven, Geertjan, Koerkamp, Bas Groot, and van Eijck, Casper H. J.

Published
2022
Full Text
View/download PDF

145. Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study

Author

van Hooft, Jeanin E., Bonsing, Bert A., Bosscha, Koop, Coene, Peter-Paul L.O., van Dam, Ronald M., van Dieren, Susan, Gerhards, Michael F., van Goor, Harry, de Hingh, Ignace H., Kazemier, Geert, Klaase, Joost M., Patijn, Gijs A., Scheepers, Joris J., van der Schelling, George P., Pranger, Bobby K., Busch, Olivier, Snoek, Frank, Scholten, Lianne, Latenstein, Anouk E.J., van Eijck, Casper, Erdmann, Joris, van der Harst, Erwin, Mieog, J. Sven D., Molenaar, I. Quintus, van Santvoort, Hjalmar C., DeVries, J. Hans, and Besselink, Marc G.

Published
2019
Full Text
View/download PDF

149. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial

Author

Andeweg, Caroline S., Bastiaenen, Vivian P., Bemelman, Willem A., van der Bilt, Jarmila D.W., Bloemen, Johanne, den Boer, Frank C., Boerma, Djamila, ten Bokkel Huinink, Daan, Brokelman, Walter J.A., Cense, Huib A., Consten, Esther C.J., Creemers, Geert-Jan, Crolla, Rogier M.P.H., Dekker, Jan-Willem T., Demelinne, Jennifer, van Det, Marc J., van Diepen, Karin K., Diepeveen, Marjolein, van Duyn, Eino B., van den Ende, Esther D., Evers, Pauline, van Geloven, Anna A.W., van der Harst, Erwin, Heemskerk, Jeroen, Heikens, Joost T., Hess, Daniel A., Inberg, Bas, Jansen, Jan, Kloppenberg, Frank W.H., Kootstra, Thomas J.M., Kortekaas, R.T.J., Los, Maartje, Madsen, Eva V.E., van der Mijle, H.C.J., Mol, Linda, Neijenhuis, Peter A., Nienhuijs, Simon W., van den Nieuwenhof, Loes, Peeters, Koen C.M.J., Polle, Sebastiaan W., Pon, Jolien, Poortman, Pieter, Radema, Sandra A., van Ramshorst, Bert, de Reuver, Philip R., Rovers, Koen P., Schmitz, Roderick F., Sluiter, Nina, Sommeijer, Dirkje W., Sonneveld, D.J.A., van Sprundel, T.C., Veltkamp, Sanne C., Vermaas, Maarten, Verwaal, Victor J., Wassenaar, Emma, Wegdam, Johannes A., de Wilt, Johannes H.W., Westerterp, Marinke, Wit, Fennie, Witkamp, Arjen J., van Woensdregt, Karlijn, van der Zaag, Edwin S., Zournas, Mandy, Klaver, Charlotte E L, Wisselink, Daniel D, Punt, Cornelis J A, Snaebjornsson, Petur, Crezee, Johannes, Aalbers, Arend G J, Brandt, Alexandra, Bremers, Andre J A, Burger, Jacobus W A, Fabry, Hans F J, Ferenschild, Floris, Festen, Sebastiaan, van Grevenstein, Wilhelmina M U, Hemmer, Patrick H J, de Hingh, Ignace H J T, Kok, Niels F M, Musters, Gijsbert D, Schoonderwoerd, Lotte, Tuynman, Jurriaan B, van de Ven, Anthony W H, van Westreenen, Henderik L, Wiezer, Marinus J, Zimmerman, David D E, van Zweeden, Annette A, Dijkgraaf, Marcel G W, and Tanis, Pieter J

Published
2019
Full Text
View/download PDF

150. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study

Author

van Veldhuisen, Eran, Walma, Marieke S., van Rijssen, L. Bengt, Busch, Olivier R., Bruijnen, Rutger C.G., van Delden, Otto M., Mohammad, Nadia Haj, de Hingh, Ignace H., Yo, Lonneke S., van Laarhoven, Hanneke W., van Leeuwen, Maarten S., Nio, C. Yung, van Santvoort, Hjalmar C., de Vries, Jan, Wessels, Frank J., Wilmink, Johanna W., Molenaar, I. Quintus, Besselink, Marc G., and van Lienden, Krijn P.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results